Recombinant COVID-19 vaccine, attenuated Influenza virus vector (Changchun Baike)

重组减毒流感病毒载体新型冠状病毒疫苗（长春百克）

Report date: 2022/04/18 15:04:04

Base Information

Drug NameRecombinant COVID-19 vaccine, attenuated Influenza virus vector (Changchun Baike)

Drug Alias NameN/A

ClassificationVaccines > Development/production technology > Recombinant vector vaccineVaccines > Application > Prophylactic vaccineVaccines > Biological material > Viral vaccine

Mechanisms of ActionImmunostimulants

TargetsNot applicable

Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesChangchun Bcht Biotechnology Co

China Registration ClassN/A

Develop Information

Active CompaniesChangchun Bcht Biotechnology Co

Inactive CompaniesN/A

Active IndicationsCoronavirus Disease 2019 (COVID-19)

Inactive IndicationsN/A

Other Information

ATC CodeN/A